Recommendation of the President – Trodelvy (sacituzumab govitecan)

On 31 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 118/2024 on the appraisal of the drug Trodelvy (sacituzumab govitecan) under drug program B.9.FM. Treatment of patients with breast cancer (ICD-10: C50)

Publication in Public Information Bulletin (BIP) >>